In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bicycle Therapeutics PLC

www.bicycletherapeutics.com

Latest From Bicycle Therapeutics PLC

Deal Watch: Coronavirus Collaborations Reflect Industry’s Full Press Pandemic Response

Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.

Deals Coronavirus COVID-19

A Backstage View Of Roche’s Recent Collaborations

In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.

Business Strategies Companies

Deal Watch: Genentech Sees Bicycle As Route To Novel Targeted Cancer Immunotherapies

Genentech pays $30m up front in a collaboration with Bicycle in a deal that could bring the UK biotech roughly $1.7bn in total. Also, deals involving Nimble, Seattle Genetics, Five Prime, Fresenius, Vifor, Yuhan, Imnewrun, Paratek, Almirall, MBD, AzothBio, Norgine, Faes, Aspen Pharmacare, Swixx.

Deals Business Strategies

Astellas, Seattle Genetics Break Ground With US ADC Approval

Co-developers gain nod for novel antibody-drug conjugate that provides new option for patients with advanced form of bladder cancer.

Cancer United States
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Respiratory, Pulmonary
  • Alias(es)
  • Bicycle Therapeutics Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Bicycle Therapeutics PLC
  • Senior Management
  • Kevin Lee, PhD, CEO
    Lee Kalowski, Pres. & CFO
    Nicholas Keen, PhD, CSO
    Michael Skynner, PhD, COO
    Nigel Crockett, PhD, CBO
  • Contact Info
  • Bicycle Therapeutics PLC
    Phone: (44) 1223 261503
    Babraham Research Campus, B900
    Meditrina Bldg.
    Cambridge, CB22 3AT
    UK
UsernamePublicRestriction

Register